Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Yesterday 11:00
BRIEF-Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209 Oct 23 (Reuters) - Zymeworks Inc. ZYME.O:
ZYMEWORKS: ENTERS EXCLUSIVE GLOBAL LICENSE & COLLABORATION AGREEMENT WITH ROCHE FOR ZW209, A TRISPECIFIC T CELL ENGAGER TARGETING DLL3
ZYMEWORKS: TO GET $55 MILLION UPFRONT PAYMENT & $40 MILLION PAYMENT UPON INITIATION OF PHASE 1B TRIAL
ZYMEWORKS: POTENTIAL TO GET UP TO $718 MILLION IN ADDITIONAL DEVELOPMENT, COMMERCIAL & SALES-BASED MILESTONES UNDER ROCHE DEAL
ZYMEWORKS: ELIGIBLE TO GET TIERED HIGH-SINGLE-DIGIT TO MID-TEEN ROYALTIES ON GLOBAL NET SALES PROTECTED BY PATENTS EXTENDING INTO 2040S
ZYMEWORKS: ROCHE TO FUND PHASE 1A TRIAL & HAVE EXCLUSIVE RIGHT TO DEVELOP & COMMERCIALIZE ZW209 GLOBALLY
Further company coverage: ZYME.O
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey